Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Joyce M. van Dodewaard-de Jong; Saskia J. A. M. Santegoets; Peter M. van de Ven; Jurjen Versluis; Henk M. W. Verheul; Tanja D. de Gruijl; Winald R. Gerritsen; Alfons J. M. van den Eertwegh

doi:10.1080/2162402X.2015.1105431

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Joyce M. van Dodewaard-de Jong, Saskia J. A. M. Santegoets, Peter M. van de Ven, Jurjen Versluis, Henk M. W. Verheul, Tanja D. de Gruijl, Winald R. Gerritsen, Alfons J. M. van den Eertwegh

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Journal	OncoImmunology
Volume	5
Issue number	4
DOIs	https://doi.org/10.1080/2162402X.2015.1105431
Publication status	Published - 2016

Access to Document

10.1080/2162402X.2015.1105431

Cite this

van Dodewaard-de Jong, J. M., Santegoets, S. J. A. M., van de Ven, P. M., Versluis, J., Verheul, H. M. W., de Gruijl, T. D., Gerritsen, W. R., & van den Eertwegh, A. J. M. (2016). Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology, 5(4). https://doi.org/10.1080/2162402X.2015.1105431

van Dodewaard-de Jong, Joyce M. ; Santegoets, Saskia J. A. M. ; van de Ven, Peter M. ; Versluis, Jurjen ; Verheul, Henk M. W. ; de Gruijl, Tanja D. ; Gerritsen, Winald R. ; van den Eertwegh, Alfons J. M. / Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. In: OncoImmunology. 2016 ; Vol. 5, No. 4.

@article{5268cb94731549d7995abf9ec5888ad4,

title = "Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells",

keywords = "Cancer vaccines, chemotherapy, docetaxel, GVAX, immunotherapy, mitoxantrone, prostate cancer",

author = "{van Dodewaard-de Jong}, {Joyce M.} and Santegoets, {Saskia J. A. M.} and {van de Ven}, {Peter M.} and Jurjen Versluis and Verheul, {Henk M. W.} and {de Gruijl}, {Tanja D.} and Gerritsen, {Winald R.} and {van den Eertwegh}, {Alfons J. M.}",

year = "2016",

doi = "10.1080/2162402X.2015.1105431",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

van Dodewaard-de Jong, JM, Santegoets, SJAM, van de Ven, PM, Versluis, J, Verheul, HMW , de Gruijl, TD, Gerritsen, WR & van den Eertwegh, AJM 2016, 'Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells', OncoImmunology, vol. 5, no. 4. https://doi.org/10.1080/2162402X.2015.1105431

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. / van Dodewaard-de Jong, Joyce M.; Santegoets, Saskia J. A. M.; van de Ven, Peter M.; Versluis, Jurjen; Verheul, Henk M. W.; de Gruijl, Tanja D.; Gerritsen, Winald R.; van den Eertwegh, Alfons J. M.

In: OncoImmunology, Vol. 5, No. 4, 2016.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

AU - van Dodewaard-de Jong, Joyce M.

AU - Santegoets, Saskia J. A. M.

AU - van de Ven, Peter M.

AU - Versluis, Jurjen

AU - Verheul, Henk M. W.

AU - de Gruijl, Tanja D.

AU - Gerritsen, Winald R.

AU - van den Eertwegh, Alfons J. M.

PY - 2016

Y1 - 2016

KW - Cancer vaccines

KW - chemotherapy

KW - docetaxel

KW - GVAX

KW - immunotherapy

KW - mitoxantrone

KW - prostate cancer

U2 - 10.1080/2162402X.2015.1105431

DO - 10.1080/2162402X.2015.1105431

M3 - Article

C2 - 27141390

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 4

ER -